A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are: Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002 . Participants will: Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms

NCT Number	NCT07726212
Lead Sponsor	Hangzhou MacroLink Biopharmaceutical LLC
Conditions	Advanced Esophageal Cancer, Advanced Lung Cancer
Enrollment	143 participants
Start Date	2026-09
Primary Completion	2027-12 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-27